Phase III trial shows pembrolizumab preferable to ipilimumab in advanced melanoma

Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma

New immunotherapy yields long-lasting responses in some patients with advanced melanoma

Investigational immunotherapy drug combo safe with early signs of effectiveness in advanced melanoma

Chk1 inhibition combined with standard dose gemcitabine may be safe and effective

Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma

Pembrolizumab is better than ipilimumab for advanced melanoma in phase III trial

BRAF 'behind the scenes' in melanoma: A scientific story of discovery

Connecting science, practice and patient outcomes: Use of BRAF inhibitors for treating metastatic melanoma in clinical practice

Response and resistance with BRAF inhibitors: Mechanisms, markers and unanswered questions

ecancermedicalscience editor's choice for February 2015

The role of health economics in cancer outcomes research